Glioblastoma Multiforme

Search Term: Glioblastoma Multiforme
Search results are returned below separately for clinical trials, frequently asked questions, pages on this site, and news articles - scroll down to see them all!

[Sponsored Links]
For People with Newly Diagnosed Glioblastoma Multiforme
NovoCure Trial The NovoTTF is a portable, investigational external device for cancer treatment using Tumor Treating Fields. The device is used in addition to the standard treatments.
For People with Reccurent Glioblastoma Multiforme (and other malignant gliomas)
Toca 511 with 5-FC: Clinical trials in progress for recurrent malignant glioma. Click here to learn more.

Trials and Noteworthy Treatments


	Treatment Next 25	Location	Last Updated

Details	Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)	Graz, Austria Prague, Czech Republic Lyon, France Paris, France Toulouse, France Hamburg, Germany Heidelberg, Germany Kiel, Germany Tel Aviv, Israel Milan, Italy Milan, Italy Rome, Italy Lanne, Switzerland La Jolla, CA Los Angeles, CA Orlando, FL Tampa, FL Chicago, IL Boston, MA Boston, MA Burlington, MA Scarborough, ME Edison, NJ New York, NY New York, NY Cleveland, OH Danville, PA Pittsburgh, PA Dallas, TX Houston, TX Houston, TX Houston, TX Seattle, WA	04/29/2012

Details	Plexxicon, Inc - A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma	San Francisco, CA	04/24/2012

Details	A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Tumors of the Brain	San Francisco, CA	04/05/2012

Details	A Phase I Ascending Dose Trial of the safety and Tolerability of Toca-511 in Patients with Recurrent Glioblastoma Multiforme	San Francisco, CA	04/05/2012

Details	A Phase II study of BKM120 for patients with recurrent glioblastoma and activated PI3K pathway at first relapse	San Francisco, CA	04/05/2012

Details	ABTC1002 - A Phase I/II Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma	San Francisco, CA	04/05/2012

Details	N0874/ABTC09-02: Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma	San Francisco, CA	04/05/2012

Details	Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma	New York, NY	03/10/2012

Details	A Phase 1 and 2 Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain	Springfield, IL	02/26/2012

Details	A Study of ICT-107(Vaccine therapy) in Glioblastoma Multiforme (GBM)	Birmingham, AL Tucson, AZ La Jolla, CA Los Angeles, CA Tampa, FL Chicago, IL Chicago, IL Louisville, KY Winston-Salem, NC Edison, NJ New Brunswick, NJ Summit, NJ Great Neck & Commack, NY Cleveland, OH Cleveland, OH Hershey, PA Philadelphia, PA Dallas, TX Houston, TX Charlottesville, VA	02/26/2012

Details	Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer	Duarte, CA Los Angeles, CA Newport Beach, CA Sacramento, CA Washington, DC Chicago, IL Chicago, IL Peoria, IL Ann Arbor, MI Detroit, MI Minneapolis, MN Kansas City, MO St. Louis, MO Chapel Hill, NC Summit, NJ Great Neck & Commack, NY Manhasset, NY Rochester, NY White Plains, NY Cincinnati, OH Cleveland, OH Columbus, OH Philadelphia, PA Charleston, SC Nashville, TN Nashville, TN Dallas, TX Seattle, WA	02/26/2012

Details	Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma	Nashville, TN	02/19/2012

Details	A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent Glioblastoma Multiforme	La Jolla, CA Los Angeles, CA San Francisco, CA Cleveland, OH	02/01/2012

Details	Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor (Toca 511)	Los Angeles, CA Detroit, MI Edison, NJ Columbus, OH Seattle, WA	02/01/2012

Details	Phase 2 Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma	Lenexa, KS	06/09/2011

Details	Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme	San Antonio, TX	05/24/2011

Details	2009-0759: A Phase 2 Open-Label Study of TPI 287 in Patients with Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy with Radiation plus Temozolomide	Houston, TX	05/11/2011

Details	Dendritic Cell Cancer Vaccine for High-grade Glioma	Innsbruck, Austria	05/05/2011

Details	A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma	San Francisco, CA	05/04/2011

Details	Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma	Boston, MA	05/04/2011

Details	Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis	,	05/04/2011

Details	A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors	New York, NY	03/10/2011

Details	Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma	Anchorage, AK Mobile, AL Phoenix, AZ Berkeley, CA Berkeley, CA Concord, CA Duarte, CA Modesto, CA Orange, CA Pomona, CA Rancho Cardova, CA Sacramento, CA San Francisco, CA Walnut Creek, CA Colorado Springs, CO Fort Collins, CO New Haven, CT Norwich, CT Fort Lauderdale, FL Jacksonville, FL Jacksonville, FL Jacksonville, FL Stuart, FL Altanta, GA Atlanta, GA Savannah, GA Cedar Rapids, IA Des Moines, IA Des Moines, IA Boise, ID Arlington Heights, IL Chicago, IL Harvey, IL Moline, IL Naperville, IL Bloomington, IN Fort Wayne, IN Indianapolis, IN Indianapolis, IN Indianapolis, IN South Bend,, IN Overland Park, KS Wichita, KS New Orleans, LA Shreveport, LA Fall River, MA Annapolis, MD Baltimore, MD Ann Arbo, MI Kalamazoo, MI Lambertville, MI Lansing, MI Royal Oak, MI Rochester, MN Saint Cloud, MN Cape Girardeau, MO Kansas City, MO Pascagoula, MS Billings, MT Asheville, NC Charlotte, NC Charlotte, NC Fargo, ND Kearney, NE Omaha, NE Omaha, NE Omaha, NE Omaha, NE Concord, NH Lebanon, NH Manchester, NH Red Bank, NJ Albuquerque, NM Albuquerque, NM Las Vegas, NV Reno, NV Brooklyn, NY Rochester, NY Stony Brook, NY Akron, OH Akron, OH Akron, OH Canton, OH Canton, OH Cincinnati, OH Cleveland, OH Cleveland, OH Cleveland, OH Cleveland, OH Columbus, OH Sylvania, OH Abington, PA Allentown, PA Bethlehem, PA Bryn Mawr, PA Danville, PA Gettysburg, PA Hershey, PA McKeesport, PA Monroeville, PA Philadelphia, PA Philadelphia, PA Pittsburgh, PA Pittsburgh, PA Pittsburgh, PA Reading, PA Wynnewood, PA Spartanburg, SC Rapid City, SD Chattanooga, TN Knoxville, TN Houston, TX Lubbock, TX San Antonio, TX Tyler, TX Murray, UT Ogden, UT Saint George, UT Salt Lake City, UT Burlington, VT Bellingham, WA Bremerton, WA Seattle, WA Seattle, WA Yakima, WA Appleton, WI La Crosse, WI Madison, WI Marshfield, WI Marshfield, WI Milwaukee, WI	03/03/2011

Details	A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas	Bethesda, MD	02/23/2011

Details	A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas	Houston, TX	12/20/2010

News Stories

(Relevance) Question - click to see the response!
Displaying 1 to 26 of 120
Click HERE for Next 25 articles!

(Relevance) Page Title - click title to go to the page!

(0.8658) Treatment Outcomes of Glioblastoma Multiforme at Community Based Teaching Hospital
(0.8658) Inotek Pharmaceuticals Announces Commencement of Enrollment in Phase 1b/2a Trial for Glioblastoma Multiforme
(0.8510) Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII...
(0.8351) Initial Experience Involving Treatment and Retreatment With Carmustine Wafers in Combination With Oral Temozolomide: Long-term Survival in a Child With Re lapsed Glioblastoma Multiforme.
(0.8351) Antiparasitic Mebendazole Shows Survival Benefit in 2 Preclinical Models of Glioblastoma Multiforme.
(0.8351) Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy.
(0.8351) Selective Serotonin Reuptake Inhibitors, Glioblastoma Multiforme, and Impact on Toxicities and Overall Survival: The Mayo Clinic Experience.
(0.8351) Nanobiotix Reports ‘Proof of Concept’ for Its Nanoparticles in Treating Glioblastoma Multiforme (Brain Cancer)
(0.8351) State-of-the-Art Therapy for Glioblastoma Multiforme
(0.8351) Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma.
(0.8351) Novocure™ Establishes Initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields (TTFields)™ Therapy
(0.8351) Adding Chloroquine to Conventional Chemotherapy and Radiotherapy for Glioblastoma Multiforme
(0.8351) Mayo Clinic Cancer Center -- Harnessing the Measles Virus to Attack Cancer Seeking a Cure for Glioblastoma Multiforme, Other Deadly Cancers
(0.8351) Panzem Gets Orphan Drug Status for Glioblastoma Multiforme
(0.8351) Phase II Trial of Radiosurgery to Magnetic Resonance Spectroscopy-Defined High-Risk Tumor Volumes in Patients with Glioblastoma Multiforme.
(0.8351) Phase II Trial of Gliadel Plus O⁶-Benzylguanine (O⁶-BG) for Patients With Recurrent Glioblastoma Multiforme
(0.8351) Combination of Gleevec® and Hydrea® Offers Promise for Glioblastoma Multiforme
(0.8351) TEMODAL(R) Approved in European Union For Treatment of Newly Diagnosed Glioblastoma Multiforme
(0.8351) Protein Upped Immune Cells, Slowed Growth of Glioblastoma Multiforme
(0.8351) Adding Temozolomide (Temodar®) to Radiation Increases Survival in Glioblastoma Multiforme
(0.8351) Clinical Cases in Neurology From Johns Hopkins Case 5: Altered Mental Status and Fever After Resection of Glioblastoma Multiforme
(0.8351) Therapy of Glioblastoma Multiforme Improved by the Antimutagenic Chloroquine
(0.8351) Erlotinib (Tarceva®) Produces Responses in Glioblastoma Multiforme
(0.8351) Tarceva® Produces Responses in Recurrent Glioblastoma Multiforme
(0.8351) Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme

Frequently Asked Questions

(Relevance) Question - click to see the response!
Displaying 1 to 11 of 11

  (0.7967) What is your opinion on Dr Burzynskis antineoplaston therapy for brain tumors?

  (0.7967) How do you get a brain tumor? What can you do to treat a brain tumor? Can you prevent a brain tumor? Will it ever just go away by itself? Why do you go into a coma? How long are you in a coma before you die? What percent of Americans have brain tumors? Is it likely since my great grandmother had a brain tumor that I will?

  (0.7967) My husband was diagnosed with Glioblastoma Multiforme about 4 months ago. He has had surgery, radiation and chemotherapy; right now we are waiting to have an MRI done. He had his last treatment in August. What is next? What can I expect from here? Are there any new treatments or research available?

  (0.7967) My sister-in-law just had surgery to remove a tumor identified as glioblastoma multiforme. The tumor was the size of a lemon. The doctor says that if it recurs, she is not a candidate for another surgery. How likely is ? What are the chances of complete recovery?

  (0.7967) Having reviewed some statistical information, I still want to know: how many GBMs are diagnosed say, in a year, or by state, or by country. If, on average, a neurosurgeon only treats one per year, they canno be THAT common, can they?

  (0.7742) My mother has been diagnosed with Glioblastoma Multiforme, tumor location: brain stem. She had a stereotactic biopsy and the doctor prescribed 40 radiation treatments with daily intake of Temodal 140mg. The radiation treatment clinic doesn~t work on weekends, so she goes 5 weekdays and pauses for 2 day week-end. However, the doctor told her to take Temodal even for week-ends till the rest of radiation treatment. That means that she would end up taking Temodal for 56 days! On the information sheet for Temodal, it is stated that Temodal should be taken for 42, up to 49 days max! Could you please tell me is it safe for my mother to take Temodal longer then 49 days? Is it safe to follow our doctor~s orders in continuing with Temodal until the end of 40 week-day radiation treatment (and end up taking Temodal for 56 days)? Should she continue taking Temodal on week-ends when she doesn~t go for radiation treatment?

  (0.7742) My friend was diagonized in early May, 2004, with Glioblastoma Multiforme. He had surgery, radiation, and chemotherapy. After radiation, they did an MRI and it showed a new growth so he started the chemotherapy and, after four chemo treatments, they did another MRI and it had gotten bigger. They now want to do another surgery and try a different chemo. Are there any significant things we should worry about with the second surgery and, since it is still growing after radiation and chemotherapy, what are his chances of survival and how long?

  (0.7742) What is the difference between diffuse astrocytoma grade three, a GBM, and AA grade three? Is it common for low white counts and low platelet counts to continually delay temodar treatments by a couple of weeks?

  (0.7742) My 57-year-old brother has Glioblastoma Multiforme. He is on steroids and has been since Oct. Within the last five weeks, he has been bruising easily/bleeding on his lower arms and wrists. Does anyone know how this can be prevented? All he is done thus far is cover his lower arms with gauze! If someone could get back to me before 4:00 p.m. today, it would be greatly appreciated! Also, as long as we are on the subject, does anyone know of a doctor in New Jersey that is willing to work "outside the box" and supplement chemotherapy with additives, such as verapimil, tamoxifen, etc.?

  (0.7742) My father was diagnosed with Glioblastoma Multiforme in mid-December 2003. The tumor is located in the left frontoparietal area and was thus deemed inoperable. He is about to begin the sixth and final week of radiation. He has also gone through his first round of chemotherapy (Temodar). During the course of his treatment, he has been going to work daily. Over the course of the last five weeks, his right side mobility had improved substantially and his radio-oncologist expressed cautious optimism regarding his prognosis. However, just as he is to begin his sixth week of radiation, he lost his balance twice and fell, and has lost some of the movement in his right arm. My question is: what can cause such deterioration of his neurological condition? Can it be explained by exhaustion, a side-effect of the treatment, or that the treatment has not halted the tumor's growth?

  (0.7742) My father has just been diagnosed with Glioblastoma Multiforme. He is starting radiation tomorrow. I want to get him on some nutritional supplements to help out with energy, weight loss, hair loss, etc. I have some specific products from a company for which I am an Independent Distributor. Some of the products do have herbs in them. My first question is: my sister's concern that some herbs will make the tumor grow more. Have you ever heard of anything to this effect? Then secondly, I am under the impression that antioxidants are not absorbed when going through radiation treatment. Is this correct or does it hinder the radiation treatment in any way? I ask because the multivitamin I would like him to take does have antioxidants in it. Maybe I should be asking a nutritionist this. Any thoughts on this?